GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qurient Co Ltd (XKRX:115180) » Definitions » EV-to-EBITDA

Qurient Co (XKRX:115180) EV-to-EBITDA : -3.51 (As of Jun. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Qurient Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Qurient Co's enterprise value is ₩69,979 Mil. Qurient Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-19,952 Mil. Therefore, Qurient Co's EV-to-EBITDA for today is -3.51.

The historical rank and industry rank for Qurient Co's EV-to-EBITDA or its related term are showing as below:

XKRX:115180' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.98   Med: -4.13   Max: -1.59
Current: -3.51

During the past 10 years, the highest EV-to-EBITDA of Qurient Co was -1.59. The lowest was -14.98. And the median was -4.13.

XKRX:115180's EV-to-EBITDA is ranked worse than
100% of 459 companies
in the Biotechnology industry
Industry Median: 8.66 vs XKRX:115180: -3.51

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-25), Qurient Co's stock price is ₩3595.00. Qurient Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-869.502. Therefore, Qurient Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Qurient Co EV-to-EBITDA Historical Data

The historical data trend for Qurient Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qurient Co EV-to-EBITDA Chart

Qurient Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.04 -12.12 -9.59 -3.85 -4.00

Qurient Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.19 -3.80 -2.66 -4.00 -4.71

Competitive Comparison of Qurient Co's EV-to-EBITDA

For the Biotechnology subindustry, Qurient Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qurient Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qurient Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Qurient Co's EV-to-EBITDA falls into.



Qurient Co EV-to-EBITDA Calculation

Qurient Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=69979.358/-19951.762
=-3.51

Qurient Co's current Enterprise Value is ₩69,979 Mil.
Qurient Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-19,952 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qurient Co  (XKRX:115180) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Qurient Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3595.00/-869.502
=At Loss

Qurient Co's share price for today is ₩3595.00.
Qurient Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-869.502.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Qurient Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Qurient Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Qurient Co (XKRX:115180) Business Description

Traded in Other Exchanges
N/A
Address
C-dong 8th Floor, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KOR, 13487
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Qurient Co (XKRX:115180) Headlines

No Headlines